# US 2013/0280262 A1 · Polypeptides and their Use in Treating and Limiting Respiratory Syncytial Virus Infection > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0280262 A1 - Document ID: US20130280262A1 - Status: Published application - Kind: A1 - Application number: 13/878,122 - Filed: 2011-10-06 - Published: 2013-10-24 - Earliest claimed: 2010-10-06 - Assignees: University of Washington through its Center for Commercialization - Inventors: William R. Schief; Bruno E. Correia; David Baker - Web page: https://patentgrep.com/patent/US20130280262A1 ## CPC - C07K 14/001: {by chemical synthesis} - A61K 39/12: Viral antigens - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - C07K 14/005: from viruses - G16B 15/00: ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment - G16B 15/20: Protein or domain folding - G16B 15/30: Drug targeting using structural data; Docking or binding prediction - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 2039/552: {Veterinary vaccine} - A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59} - A61K 2039/6075: {Viral proteins} - C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides polypeptides and compositions thereof for treating or limiting respiratory syncytial virus infection, and computational methods for designing such polypeptides. ## Claims ### Claim 1 An isolated polypeptide, comprising an amino acid sequence according to SEQ ID NO:1 ### Claim 2 (depends on 1) The isolated polypeptide of claim 1, comprising an amino acid sequence according to SEQ ID NO:2. ### Claim 3 (depends on 1) The isolated polypeptide of claim 1, comprising an amino acid sequence according to SEQ ID NO:3. ### Claim 4 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NOS:4-9. ### Claim 5 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9. ### Claim 6 (depends on 1) The isolated polypeptide of claim 1, wherein the polypeptide comprises a sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:7, and SEQ ID NO:9. ### Claim 7 (depends on 1) A virus-like particle (VLP) comprising the polypeptide of claim 1. ### Claim 8 (depends on 1) An isolated nucleic acid encoding the polypeptide of claim 1. ### Claim 9 (depends on 8) A recombinant expression vector comprising the isolated nucleic acid of claim 8 operatively linked to a promoter. ### Claim 10 (depends on 9) A recombinant host cell comprising the recombinant expression vector of claim 9. ### Claim 11 (depends on 1) A pharmaceutical composition, comprising the polypeptide of claim 1, and a pharmaceutically acceptable carrier. ### Claim 12 (depends on 1) A method for treating a respiratory syncytial virus (RSV) infection, comprising administering to a subject infected with RSV an amount effective to treat the infection of the polypeptide of claim 1. ### Claim 13 (depends on 1) A method for limiting development of an RSV infection, comprising administering to a subject at risk of RSV infection an amount effective to limit development of an RSV infection of the polypeptide of claim 1. ### Claim 14 (depends on 1) A method for generating an immune response in a subject, comprising administering to the subject an amount effective to generate an immune response of the polypeptide of claim 1. ### Claim 15 (depends on 8) A pharmaceutical composition, comprising (a) the isolated nucleic acid of claim 8; and (b) a pharmaceutically acceptable carrier. ### Claim 16 (depends on 1) A method for monitoring an RSV-induced disease in a subject and/or monitoring response of the subject to immunization by an RSV vaccine, comprising contacting the polypeptide of claim 1 with a bodily fluid from the subject and detecting RSV-binding antibodies in the bodily fluid of the subject. ### Claim 17 (depends on 16) The method of claim 16, wherein the bodily fluid comprises serum or whole blood. ### Claim 18 (depends on 1) A method for detecting RSV binding antibodies, comprising (a) contacting the polypeptide of claim 1 with a composition comprising a candidate RSV binding antibody under conditions suitable for binding of RSV antibodies to the polypeptide, VLP, or composition; and (b) detecting RSV antibody complexes with the polypeptide, VLP, or composition. ### Claim 19 (depends on 18) The method of claim 18, further comprising isolating the RSV antibodies. ### Claim 20 (depends on 1) A method for producing RSV antibodies, comprising (a) administering to a subject an amount effective to generate an antibody response of the polypeptide of claim 1; and (b) isolating antibodies produced by the subject. ### Claim 21 A computational method for designing a polypeptide scaffold, comprising (a) defining a polypeptide structural motif to be used as a folding nucleus; (b) defining (i) a target three dimensional topology for a polypeptide scaffold compatible with the polypeptide structural motif, and (b) a region of the target three dimensional topology to be replaced by the polypeptide structural motif; (c) growing an extended polypeptide chain from termini of atomic coordinates of the polypeptide structural motif; (d) folding the extended polypeptide chain while maintaining backbone dihedral angles of the polypeptide structural motif fixed; and (e) identifying folded polypeptide chains that meet a user-defined threshold of polypeptide backbone root mean square deviation (rmsd) relative to the target three-dimensional topology as polypeptide scaffolds of interest. ### Claim 22 (depends on 21) The method of claim 21, further comprising determining one or more constraints from the target three-dimensional topology prior to growing the extended polypeptide chain. ### Claim 23 (depends on 21) The method of claim 21, further comprising recovering original side-chain conformations within the structural motif and keeping them fixed throughout 1 or more rounds of iterative folding and full-atom optimization. ### Claim 24 (depends on 21) A non-transitory machine readable storage medium, comprising a set of instructions for causing a computing device to carry out the computational methods of claim 21.